In fiscal year 2025, IMBiologics (493280) reported revenue of 11.6 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 11.6 billion KRW | 298 million KRW | 877 million KRW | [source] |
| 2024 | 27.6 billion KRW | 14.0 billion KRW | -11.9 billion KRW | — |
| 2023 | — | -8.6 billion KRW | -48.5 billion KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 75.3 billion KRW | 1.8 billion KRW | 73.5 billion KRW | [source] |
| 2024 | — | — | — | — |
| 2023 | — | — | — | — |
This company has no revenue account in the DART financial statements. Industry-specific accounts such as insurance or interest income are not converted to revenue.
Years without a source link are outside the DART financial API collection period.